Compile Data Set for Download or QSAR
maximum 50k data
Found 333 Enz. Inhib. hit(s) with all data for entry = 229
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237552(US10052306, 223 | rac-(3aR,5r,6aS)-5-(4- chloroben...)
Affinity DataIC50:  11.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238867(US10052306, 306 | rac-4-{2-[(3aR,5R,6aS)- 5-benzyl...)
Affinity DataIC50:  11.7nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238862(US10052306, 301 | rac-4-{2-[(3aR,5S,6aS)- 5-benzyl...)
Affinity DataIC50:  12.2nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237388(US10052306, 204 | rac-(3aR,5r,6aS)-2-(2- hydroxy-2...)
Affinity DataIC50:  12.6nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238861(US10052306, 300 | rac-4-(2-((3aR,6aS)-5- benzylhex...)
Affinity DataIC50:  13.9nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237683(US10052306, 229 | rac-(3aR,5r,6aS)-5-(2- fluoroben...)
Affinity DataIC50:  15.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238865(US10052306, 304 | rac-4-{2-[(3aR,5S,6aS)- 5-benzyl...)
Affinity DataIC50:  16.8nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM235335(US10052306, 131 | US10052306, 281 | rac-(3aR,5r,6a...)
Affinity DataIC50:  17.4nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237322(US10052306, 168 | rac-(3aR,5r,6aS)-5-(4- fluoroben...)
Affinity DataIC50:  17.8nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237551(US10052306, 222 | rac-2-(2-(3-fluoro-4- hydroxyphe...)
Affinity DataIC50:  19.3nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238863(US10052306, 302 | rac-4-{2-[(3aR,5R,6aS)- 5-benzyl...)
Affinity DataIC50:  20.1nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM235341((3aR,5S,6aS)-5-benzyl-2- ((S)-2-hydroxy-2-(4- hydr...)
Affinity DataIC50:  20.4nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM235341((3aR,5S,6aS)-5-benzyl-2- ((S)-2-hydroxy-2-(4- hydr...)
Affinity DataIC50:  20.4nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237325(US10052306, 171 | rac-(3aR,5r,6aS)-2-(2-(3- fluoro...)
Affinity DataIC50:  22.1nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237334((3aR,5R,6aS)-5-benzyl-2- ((R)-2-(3-fluoro-4- hydro...)
Affinity DataIC50:  22.3nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238859(US10052306, 298 | rac-6-(2-{5-benzyl- octahydrocyc...)
Affinity DataIC50:  22.4nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM235340((3aR,5R,6aS)-5-benzyl-2- ((R)-2-hydroxy-2-(4- hydr...)
Affinity DataIC50:  23.7nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM235340((3aR,5R,6aS)-5-benzyl-2- ((R)-2-hydroxy-2-(4- hydr...)
Affinity DataIC50:  23.7nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237699(US10052306, 245 | rac-5-(2,4- difluorobenzyl)-2-(2...)
Affinity DataIC50:  23.8nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237709((3aR,5S,6aS)-5-(4- fluorobenzyl)-2-((S)-2- hydroxy...)
Affinity DataIC50:  24nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM235335(US10052306, 131 | US10052306, 281 | rac-(3aR,5r,6a...)
Affinity DataIC50:  25.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237544(US10052306, 215 | rac-2-(2-hydroxy-2-(5- hydroxypy...)
Affinity DataIC50:  25.7nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM235352(US10052306, 144 | rac- (3aR,5r,6aS)-5- benzyl-2-(2...)
Affinity DataIC50:  26.8nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238874(US10052306, 313 | rac-4-(2-((3aR,5r,6aS)-5- benzyl...)
Affinity DataIC50:  26.9nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM235339(US10052306, 135 | rac-(3aR,5r,6aS)-5-(4- fluoroben...)
Affinity DataIC50:  27.1nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237554(2-((3aR,5r,6aS)-5-(2- fluorobenzyl)-5- hydroxyhexa...)
Affinity DataIC50:  27.3nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237379(US10052306, 195 | rac-(3aR,5r,6aS)-2-(2- hydroxy-2...)
Affinity DataIC50:  28.7nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237687(US10052306, 233 | rac-(3aR,5r,6aS)-5-(2,4- difluor...)
Affinity DataIC50:  29.9nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM236487((3aR,5S,6aS)-5-benzyl-2- ((S)-2-(3-fluoro-4- hydro...)
Affinity DataIC50:  30.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237707(US10052306, 253 | rac-(3aR,5r,6aS)-5-(3,4- difluor...)
Affinity DataIC50:  31.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237331(US10052306, 177 | rac-6-(2-((3aR,5r,6aS)-5- benzyl...)
Affinity DataIC50:  31.6nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237710((3aR,5R,6aS)-5-(4- fluorobenzyl)-2-((R)-2- hydroxy...)
Affinity DataIC50:  31.7nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237330(US10052306, 176 | rac-4-(2-((3aR,5r,6aS)-5- benzyl...)
Affinity DataIC50:  32.4nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237329(US10052306, 175 | rac-4-(2-((3aR,5r,6aS)-5- benzyl...)
Affinity DataIC50:  32.4nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237319((3aR,5R,6aS)-5-benzyl-2- ((R)-2-hydroxy-2-(5- hydr...)
Affinity DataIC50:  33.7nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237369(US10052306, 185 | rac-(3aR,5r,6aS)-2-(2- hydroxy-2...)
Affinity DataIC50:  34.9nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237545(2-[(3aR,5R,6aS)-5- hydroxy-5-{[4- (trifluoromethyl...)
Affinity DataIC50:  36nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237383(US10052306, 199 | rac-6-{2-[(3aR,5R,6aS)- 5-hydrox...)
Affinity DataIC50:  36.3nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238877(US10052306, 316 | rac-4-(2-((3aR,5s,6aS)- 5-benzyl...)
Affinity DataIC50:  36.4nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237318((3aR,5S,6aS)-5-benzyl-2- ((S)-2-hydroxy-2-(5- hydr...)
Affinity DataIC50:  38.1nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238864(2-[(3aR,5S,6aS)-5- benzyl- octahydrocyclopenta[c] ...)
Affinity DataIC50:  38.8nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM235387(US10052306, 153 | rac-6-(2-((3aR,5r,6aS)-5- benzyl...)
Affinity DataIC50:  40.2nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237682(US10052306, 228 | rac-5-(2-fluorobenzyl)-2- (2-hyd...)
Affinity DataIC50:  40.9nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238868(2-[(3aR,5S,6aS)-5- benzyl- octahydrocyclopenta[c] ...)
Affinity DataIC50:  41.2nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237366(US10052306, 182 | rac-(3aR,5R,6aS)-2-[2- hydroxy-2...)
Affinity DataIC50:  41.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237708(US10052306, 254 | rac-(3aR,5r,6aS)-5-(4- fluoro-2-...)
Affinity DataIC50:  42.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM238288(US10052306, 280 | rac-(3aR,5R,6aS)-5- benzyl-2-[2-...)
Affinity DataIC50:  43nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM235338(2-((3aR,5r,6aS)-5-(4- fluorobenzyl)-5- hydroxyhexa...)
Affinity DataIC50:  43.2nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM237368(2-[(3aR,5R,6aS)-5- hydroxy-5-[(4- methoxyphenyl)me...)
Affinity DataIC50:  43.3nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Homo sapiens (Human))
Cadent Therapeutics

US Patent
LigandPNGBDBM235334(2-((3aR,5r,6aS)-5-benzyl- 5- hydroxyhexahydrocyclo...)
Affinity DataIC50:  44.1nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 333 total ) | Next | Last >>
Jump to: